The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech; Genentech; Genentech; Genentech
 
Honoraria - Baxalta; Baxalta; Baxalta; Baxalta; Baxter; Baxter; Baxter; Baxter; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Genzyme; Genzyme; Genzyme; Genzyme; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Shire; Shire; Shire; Shire; Tesaro; Tesaro; Tesaro; Tesaro
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Hallozyme (Inst); Hallozyme (Inst); Hallozyme (Inst); Hallozyme (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; Merck; Merck; Merck; Merck; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Z and L International Medical; Z and L International Medical; Z and L International Medical; Z and L International Medical
Research Funding - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Lilly; Lilly; Lilly; Lilly
 
Jaffer A. Ajani
Honoraria - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck
Consulting or Advisory Role - American Cancer Society; American Cancer Society; American Cancer Society; American Cancer Society; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Insys Therapeutics; Insys Therapeutics; Insys Therapeutics; Insys Therapeutics; Merck; Merck; Merck; Merck; Vaccinogen; Vaccinogen; Vaccinogen; Vaccinogen
Research Funding - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Delta-Fly Pharma; Delta-Fly Pharma; Delta-Fly Pharma; Delta-Fly Pharma; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly; I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genexine; Genexine; Genexine; Genexine; Green Cross; Green Cross; Green Cross; Green Cross; Hanmi; Hanmi; Hanmi; Hanmi; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Samyang; Samyang; Samyang; Samyang; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genexine (Inst); Genexine (Inst); Genexine (Inst); Genexine (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Green Cross (Inst); Green Cross (Inst); Green Cross (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celltrion; Celltrion; Celltrion; Celltrion; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Quintiles; Quintiles; Quintiles; Quintiles; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Foundation medicine; Foundation medicine; Foundation medicine; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Jill Lacy
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene; KeyQuest Health; KeyQuest Health; KeyQuest Health; KeyQuest Health; Merck; Merck; Merck; Merck; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Jeeyun Lee
No Relationships to Disclose
 
Teresa Macarulla
No Relationships to Disclose
 
Gulam Abbas Manji
Honoraria - Celgene; Celgene; Celgene; Celgene; Exelixis; Exelixis; Exelixis; Exelixis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis; Exelixis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Exelixis; Exelixis; Exelixis; Exelixis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst)
 
Simon Allen
No Relationships to Disclose
 
Nedal Jaffer Abdulla Al-Sakaff
Employment - Roche; Roche; Roche; Roche
Stock and Other Ownership Interests - Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Roche; Roche; Roche; Roche
 
Hila Barak
Employment - Baxalta; Baxalta; Baxalta; Baxalta; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Stock and Other Ownership Interests - Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Travel, Accommodations, Expenses - Baxalta; Baxalta; Baxalta; Baxalta; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
 
Jilpa Patel
Employment - Genentech; Genentech; Genentech; Genentech
 
Jan Peter Pintoffl
Employment - Roche; Roche; Roche; Roche
 
Colby Shemesh
Employment - Genentech; Genentech; Genentech; Genentech
 
Wei Zhang
Employment - Roche; Roche; Roche; Roche
 
Xiaosong Zhang
Employment - Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Patents, Royalties, Other Intellectual Property - Patents in cancer genomics; Patents in cancer genomics; Patents in cancer genomics; Patents in cancer genomics
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
 
Ian Chau
Honoraria - Lilly; Lilly; Lilly; Lilly
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Oncologie; Oncologie; Oncologie; Oncologie; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD